KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Return on Sales (2016 - 2025)

Historic Return on Sales for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 0.0%.

  • Pfizer's Return on Sales changed 0.0% to 0.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.0%, marking a year-over-year change of 0.0%. This contributed to the annual value of 0.0% for FY2024, which is 0.0% changed from last year.
  • Per Pfizer's latest filing, its Return on Sales stood at 0.0% for Q3 2025, which was down 0.0% from 0.0% recorded in Q2 2025.
  • Pfizer's Return on Sales' 5-year high stood at 0.0% during Q2 2025, with a 5-year trough of 0.01% in Q3 2021.
  • Its 5-year average for Return on Sales is 0.0%, with a median of 0.0% in 2022.
  • Its Return on Sales has fluctuated over the past 5 years, first plummeted by -1000bps in 2021, then surged by 100bps in 2022.
  • Pfizer's Return on Sales (Quarter) stood at 0.0% in 2021, then skyrocketed by 101bps to 0.0% in 2022, then tumbled by -15111bps to 0.01% in 2023, then skyrocketed by 101bps to 0.0% in 2024, then skyrocketed by 537bps to 0.0% in 2025.
  • Its Return on Sales was 0.0% in Q3 2025, compared to 0.0% in Q2 2025 and 0.0% in Q1 2025.